Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2020 07:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports First Quarter 2020 Financial Results and Provides Updates on Antiviral Programs

- Company has sufficient capital to advance pipeline and fund operations through 2021 - BOTHELL, WA, May 14, 2020 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc (NASDAQ: COCP), (“Cocrystal” or the...
May 11, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Provides COVID-19 Impact Update on Development Programs

– Company reprioritizes activities to accelerate development and provides next steps for advancing preclinical COVID-19 Coronavirus program – – Discussions ongoing with potential strategic...
April 22, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Expands Exclusive License Agreement with Kansas State University Research Foundation to New Coronavirus Antiviral Compounds with Novel Mechanism of Action

- Expanded license agreement with KSURF further broadens and advances Cocrystal’s COVID-19 program - - Small molecule therapeutic inhibitors against coronaviruses included in agreement have...
April 20, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Directors

- Work completed over decades of renowned biochemist’s career serves as basis for Company’s structure-based technology which has demonstrated broad utility in development of proprietary antivirals - ...
April 15, 2020 08:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma to Present at the April 2020 Virtual Investor Summit

– Presentation with live audio webcast on Wednesday, April 22 at 11:00 AM ET, immediately followed by an interactive Q&A session – BOTHELL, WA,, April 15, 2020 (GLOBE NEWSWIRE) -- Cocrystal...
March 30, 2020 06:05 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Reports 2019 Financial Results and Outlines Expected Value-Driving Milestones for 2020

Advancing preclinical COVID-19 Coronavirus program leveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Continuing collaboration with Merck to discover...
March 11, 2020 09:40 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Closing of $6.8 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, March 11, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
March 09, 2020 15:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces $6.8 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, March 09, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
March 06, 2020 16:01 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Plans to Advance Coronavirus Program

Company has immediately initiated Coronavirus programLeveraging patent rights recently acquired from Kansas State University Research Foundation (“KSURF”) Strong financial position bolsters Company’s...
February 28, 2020 14:00 ET | Source: Cocrystal Pharma, Inc.

Cocrystal Pharma Announces Closing of $11.0 Million Registered Direct Offering Priced At-the-Market

BOTHELL, WA, Feb. 28, 2020 (GLOBE NEWSWIRE) -- COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral...